Erick Gamelin

Erick Gamelin

Auto-generated profile, based on publicly available information

Erick Gamelin

20Acrivon Therapeutics, Watertown, Massachusetts

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Seminars in Oncology
Verified
Journal Article
Closed access
PDF file
MBMichele Boisdron-Celle
Michele Boisdron-Celle
OCOlivier Capitain
Olivier Capitain
RFRoger Faroux
Roger Faroux
CBChristophe Borg
Christophe Borg
JMJean Philippe Metges
Jean Philippe Metges
EGErick Gamelin
Erick Gamelin

1 December 2012 in Clinical Colorectal Cancer
Verified
Journal Article
Closed access
OCOlivier Capitain
Olivier Capitain
AAAndreaa Asevoaia
Andreaa Asevoaia
MBMichele Boisdron-Celle
Michele Boisdron-Celle
APAnne-Lise Poirier
Anne-Lise Poirier
AMAlain Morel
Alain Morel
EGErick Gamelin
Erick Gamelin

23 April 2024 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
JBJames Brugarolas
James Brugarolas
GOGregory Obara
Gregory Obara
KBKathryn Beckermann
Kathryn Beckermann
BRBrian I. Rini
Brian I. Rini
ELElaine T Lam
Elaine T Lam
NTNizar M. Tannir
Nizar M. Tannir
Purpose: ARO-HIF2 is an siRNA drug designed to selectively target hypoxia-inducible factor-2α (HIF2α) interrupting downstream pro-oncogenic signaling in clear cell renal cell carcinoma (ccRCC). The aims of this Phase 1 study (AROHIF21001) were to evaluate safety, tolerability, pharmacokinetics, and establish a recommended Phase 2 dose. Patients and Methods: Subjects with ccRCC and progressive disease after at least 2 prior therapies that included VEGF and immune checkpoint inhibitors were progressively enrolled into dose-escalation cohorts of ARO-HIF2 administered intravenously at 225, 525, or 1,050 mg weekly. Results: Twenty-six subjects received ARO-HIF2. The most common treatment emergent adverse events (AE) irrespective of causality were fatigue (50.0%), dizziness (26.9%), dyspnea (23.1%), and nausea (23.1%). Four subjects (15.4%) had treatment-related serious AEs. AEs of special interest included neuropathy, hypoxia, and dyspnea. ARO-HIF2 was almost completely cleared from plasma circulation within 48 hours with minimal renal clearance. Reductions in HIF2α were observed between pre- and post-dosing tumor biopsies, but the magnitude was quite variable. The objective response rate was 7.7% and the disease control rate was 38.5%. Responses were accompanied by ARO-HIF2 uptake in tumor cells, HIF2α downregulation, as well as rapid suppression of tumor produced erythropoietin (EPO) in a patient with paraneoplastic polycythemia. Conclusions: ARO-HIF2 downregulated HIF2α in advanced ccRCC—inhibiting tumor growth in a subset of subjects. Further development was hampered by off-target neurotoxicity and low response rate. This study provides proof of concept that siRNA can target tumors in a specific manner.

25 July 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
ARAntoni Ribas
Antoni Ribas
Mohammed MilhemMohammed Milhem
Mohammed Milhem
Christopher HoimesChristopher Hoimes
Christopher Hoimes
AAAsim Amin
Asim Amin
CLChristopher D. Lao
Christopher D. Lao
GLGeorgina Venetia Long
Georgina Venetia Long
Purpose: Nelitolimod (previously SD-101) is a toll-like receptor 9 agonist. We assessed whether intratumoral nelitolimod plus pembrolizumab potentiates antitumor activity in patients with advanced melanoma who had not previously received anti–PD-1/PD-L1 therapy. Patients and Methods: Patients with advanced melanoma who were naïve to anti–PD-1/PD-L1 therapy received either nelitolimod 2 mg injected into 1 to 4 lesions or nelitolimod 8 mg injected weekly into a single lesion for 4 weekly doses and then every 3 weeks. Pembrolizumab 200 mg was administered intravenously every 3 weeks. Results: Forty-five patients received nelitolimod 2 mg and 41 patients received nelitolimod 8 mg per injection. The objective response rate (ORR) was 76% in the 2-mg group and 49% in the 8-mg group. In those with distant metastases, ORRs in both treatment groups were similar to the overall ORRs. In the 2-mg group, treatment responses were similar in those with PD-L1–positive tumors and those with PD-L1–negative tumors. The progression-free survival rate at 18 months (landmark) was 62% in the 2-mg group and 40% in the 8-mg group. Forty-four patients (100%) in the 2-mg group and 37 patients (95%) in the 8-mg group experienced a treatment-related adverse event with either drug; overall, 31 patients (37%) had a grade 3 or 4 treatment-related adverse event related to either study drug. Conclusions: In patients with anti–PD-1/PD-L1 treatment-naïve advanced melanoma, nelitolimod plus pembrolizumab induced objective responses, including in PD-L1–negative tumors. The treatment combination warrants further study in advanced melanoma.

1 October 2025
Verified
Other
Open access
PDF file
ARAntoni Ribas
Antoni Ribas
Mohammed MilhemMohammed Milhem
Mohammed Milhem
Christopher HoimesChristopher Hoimes
Christopher Hoimes
AAAsim Amin
Asim Amin
CLChristopher D. Lao
Christopher D. Lao
GLGeorgina Venetia Long
Georgina Venetia Long
Figure S3 shows best percentage changes from baseline in target lesion size, grouped by PD-L1 status, for patients treated with nelitolimod 8 mg plus pembrolizumab 200 mg. The plot highlights greater tumor shrinkage in patients with PD-L1–positive tumors

1 October 2025
Verified
Other
Open access
PDF file
ARAntoni Ribas
Antoni Ribas
Mohammed MilhemMohammed Milhem
Mohammed Milhem
Christopher HoimesChristopher Hoimes
Christopher Hoimes
AAAsim Amin
Asim Amin
CLChristopher D. Lao
Christopher D. Lao
GLGeorgina Venetia Long
Georgina Venetia Long
Table S3 reports PFS for patients with anti–PD-1/PD-L1–naive melanoma who received nelitolimod 2 mg or 8 mg and pembrolizumab 200 mg (intention-to-treat).